REVIEW Viral (HSV-1, HSV-2 and VZV) thymidine kinase converts aciclovir to the aciclovir monophosphate, which is then converted to the diphosphate by cellular guanylate kinase, and finally to the triphosphate by phosphoglycerate kinase, phosphoenolpyruvate carboxykinase, and pyruvate kinase. Aciclovir triphosphate competitively inhibits viral DNA polymerase and competes with the natural deoxyguanosine triphosphate, for incorporation into viral DNA. Once incorporated, aciclovir triphosphate inhibits DNA synthesis by acting as a chain terminator.
O'Brien JJ, Campoli-Richards DM: Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1989 Mar;37(3):233-309.
de Clercq, Erik; Field, Hugh J (5 October 2005). Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy. British Journal of Pharmacology 147 (1) (Wiley-Blackwell January 2006). pp. 1-11. doi:10.1038/sj.bjp.0706446. PMC 1615839. PMID 16284630
Schaffer, Howard; Robert Vince, S. Bittner, S. Gurwara (1971). Novel substrate of adenosine deaminase. Journal of Medicinal Chemistry 14 (4): 367-369. doi:10.1021/jm00286a024. PMID 5553754.
Elion, Gertrude; Furman, Fyfe, Miranda, Beauchamp and Schaffer (1977). Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine. Proc Natl Acad Sci USA 74 (12): 5716-5720. doi:10.1073/pnas.74.12.5716. PMC 431864. PMID 202961.
For research use only. Not for diagnostic or therapeutic use. Not for human use. AK Scientific, Inc. does not sell to individuals. If you are a first-time customer, please email for review at least two official business documents issued by your local jurisdiction, state/province, or country.